Maxcyte (MXCT) Total Liabilities (2020 - 2026)

Maxcyte (MXCT) has reported Total Liabilities for 7 consecutive years, with $25.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Liabilities fell 10.7% year-over-year to $25.9 million in Q2 2026; TTM through Jun 2026 was $25.9 million, a 10.7% decrease from a year earlier, with the FY2025 full-year figure at $31.0 million, down 6.63% from the prior year.
• Total Liabilities was $25.9 million for Q2 2026 at Maxcyte, down from $26.6 million in the prior quarter.
• Over five years, Total Liabilities peaked at $36.1 million in Q4 2023 and troughed at $25.9 million in Q2 2026.
• A 5-year average of $31.4 million and a median of $31.8 million in 2022 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities soared 135.6% in 2022 and declined 12.97% in 2026, its largest moves.
• Over 5 years, Total Liabilities stood at $32.7 million in 2022, then rose by 10.47% to $36.1 million in 2023, then fell by 8.0% to $33.2 million in 2024, then decreased by 6.63% to $31.0 million in 2025, then dropped by 16.43% to $25.9 million in 2026.
• The last three Total Liabilities figures came in at $25.9 million (Q2 2026), $26.6 million (Q1 2026), and $31.0 million (Q4 2025), per Business Quant data.